Recombinant Human Soluble RANKL (sRANKL) Launched in USA

Andover, MA, November 07, 2008 --(PR.com)-- OYC International Inc. is pleased to announce the launch of recombinant human soluble RANKL (sRANKL) to support osteoporosis and bone metabolism research initiatives.

Receptor activator of NF-kB ligand (RANKL), also designated TRANCE, OPGL and ODF, is a member of the TNF family that is expressed in osteoblasts, activated T cells, and so on. RANKL interacts with its receptor RANK expressed on osteoclast progenitors and mature dendritic cells, leading to osteoclastogenesis and T cell proliferation, respectively.

sRANKL was developed by OYC ‘s Nagahama Institute for Biomedical Sciences, Nagahama Japan. By using sRANKL, Nagahama Institute was able to establish a novel rapid osteopenia model mice, requiring only 50 h for completion of the experimental procedures. sRANKL has high activity and low endotoxin level and degree of bone loss could be controlled by changing doses of sRANKL.

sRANKL can be used in establishing osteopenia model for in vivo screening of drugs for osteoporosis, determination of effect and mechanism in bone metabolism, and evaluation of bone anabolic drugs. It is available in 20 ug or larger pack sizes.

For further information please contact OYC Americas at (978) 470-1980 or email to sacharya@oycus.com or visit www.oycus.com.

###